Entheon Biomedical Corp.
ENBI
CNSX
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -25.87% | -34.71% | 79.83% | 13.32% | -32.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.87% | -34.71% | 79.83% | 13.32% | -32.18% |
| Operating Income | 25.87% | 34.71% | -79.83% | -13.32% | 32.18% |
| Income Before Tax | 27.33% | 31.84% | -82.59% | -12.99% | 33.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.33% | 31.84% | -82.59% | -12.99% | 33.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.33% | 31.84% | -82.59% | -12.99% | 33.71% |
| EBIT | 25.87% | 34.71% | -79.83% | -13.32% | 32.18% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 52.83% | 64.21% | 9.57% | 24.18% | 55.83% |
| Normalized Basic EPS | 54.55% | 64.41% | 10.17% | 36.76% | 54.17% |
| EPS Diluted | 52.83% | 64.21% | 9.57% | 24.18% | 64.67% |
| Normalized Diluted EPS | 54.55% | 64.41% | 10.17% | 36.76% | 54.17% |
| Average Basic Shares Outstanding | 56.44% | 89.33% | 103.52% | 49.79% | 49.92% |
| Average Diluted Shares Outstanding | 56.44% | 89.33% | 103.52% | 49.79% | 49.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |